News | December 07, 2023
Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
he financing was significantly oversubscribed with high demand from both existing and new investors.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Subscribe To Our Newsletter & Stay Updated
